Literature DB >> 11288139

Nitric oxide and nitric oxide synthase in Huntington's disease.

A W Deckel1.   

Abstract

Nitric oxide (NO) is a biologically active inorganic molecule produced when the semiessential amino acid l-arginine is converted to l-citrulline and NO via the enzyme nitric oxide synthase (NOS). NO is known to be involved in the regulation of many physiological processes, such as control of blood flow, platelet adhesion, endocrine function, neurotransmission, neuromodulation, and inflammation, to name only a few. During neuropathological conditions, the production of NO can be either protective or toxic, dependent on the stage of the disease, the isoforms of NOS involved, and the initial pathological event. This paper reviews the properties of NO and NOS and the pathophysiology of Huntington's disease (HD). It discusses ways in which NO and NOS may interact with the protein product of HD and reviews data implicating NOS in the neuropathology of HD. This is followed by a synthesis of current information regarding how NO/NOS may contribute to HD-related pathology and identification of areas for potential future research. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11288139     DOI: 10.1002/jnr.1057

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  27 in total

Review 1.  NO as a signalling molecule in the nervous system.

Authors:  Juan V Esplugues
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Targeted knock-down of neuronal nitric oxide synthase expression in basal forebrain with RNA interference.

Authors:  Vasiliki Mahairaki; Leyan Xu; Mohamed H Farah; Glen Hatfield; Eddy Kizana; Eduardo Marbán; Vassilis E Koliatsos
Journal:  J Neurosci Methods       Date:  2009-02-28       Impact factor: 2.390

3.  Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.

Authors:  Fernando E Padovan-Neto; Stephen Sammut; Shreaya Chakroborty; Alexander M Dec; Sarah Threlfell; Peter W Campbell; Vishnu Mudrakola; John F Harms; Christopher J Schmidt; Anthony R West
Journal:  J Neurosci       Date:  2015-04-08       Impact factor: 6.167

Review 4.  Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity.

Authors:  V Calabrese; G Scapagnini; A M Giuffrida Stella; T E Bates; J B Clark
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

5.  Construction of a robust and sensitive arginine biosensor through ancestral protein reconstruction.

Authors:  Jason H Whitfield; William H Zhang; Michel K Herde; Ben E Clifton; Johanna Radziejewski; Harald Janovjak; Christian Henneberger; Colin J Jackson
Journal:  Protein Sci       Date:  2015-08-18       Impact factor: 6.725

6.  Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Authors:  Carlos Cepeda; Laurie Galvan; Sandra M Holley; Shilpa P Rao; Véronique M André; Elian P Botelho; Jane Y Chen; Joseph B Watson; Karl Deisseroth; Michael S Levine
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

Review 7.  Optogenetics for neurodegenerative diseases.

Authors:  Kiara T Vann; Zhi-Gang Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-04-25

Review 8.  Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.

Authors:  Andreas Wyttenbach
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

9.  S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease.

Authors:  Florian Haun; Tomohiro Nakamura; Alicia D Shiu; Dong-Hyung Cho; Taiji Tsunemi; Emily A Holland; Albert R La Spada; Stuart A Lipton
Journal:  Antioxid Redox Signal       Date:  2013-06-20       Impact factor: 8.401

Review 10.  Magnetic resonance imaging of Huntington's disease: preparing for clinical trials.

Authors:  S Klöppel; S M Henley; N Z Hobbs; R C Wolf; J Kassubek; S J Tabrizi; R S J Frackowiak
Journal:  Neuroscience       Date:  2009-01-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.